Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results
Article content
Article content
$124.2 million in cash and cash equivalents and marketable securities provides runway as of March 31, 2025
Article content
CAMBRIDGE, Mass. & MONTREAL — Repare Therapeutics Inc. ('Repare' or the 'Company') (Nasdaq: RPTX), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2025.
Article content
'During the first quarter of 2025 we continued our efforts to create long-term value for our shareholders via partnering and by advancing our novel pipeline programs,' said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. 'We announced a strategic partnership with DCx Biotherapeutics to out-license our discovery platforms, and we are exploring a full range of strategic alternatives and partnerships across our portfolio. We are well-positioned from an operational and financial standpoint to drive our clinical pipeline to key inflection points and remain on track to report initial data for both the LIONS and POLAR trials in the second half of this year.'
Article content
First Quarter 2025 and Recent Portfolio Highlights:
Article content
Announced out-licensing of its discovery platforms to DCx Biotherapeutics
Repare announced it out-licensed its early-stage discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation ('DCx'). In connection with this agreement, Repare will receive upfront and near-term payments totaling $4 million, as well as a 9.99% equity position in DCx, including certain dilution protection rights, and is eligible to receive potential future out-licensing, clinical and commercial milestone payments, as well as low single-digit sales royalties for the development of certain products by DCx. Additionally, DCx will retain approximately 20 of Repare's preclinical research employees.
Article content
RP-3467: Potential best-in-class, oral Polθ ATPase/helicase inhibitor
Repare is conducting a Phase 1 clinical trial of RP-3467 (POLAR), dosing patients alone and in combination with the poly-ADP ribose polymerase (PARP) inhibitor, olaparib. POLAR is a multicenter, open-label, dose-escalation Phase 1 clinical trial designed to investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-3647 alone or in combination with olaparib in adults with locally advanced or metastatic epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer, or pancreatic adenocarcinoma.
Upcoming expected milestone:
Q3 2025: Topline safety, tolerability and early efficacy data from the POLAR trial in monotherapy and in combination with olaparib.
Article content
RP-1664: First-in-class, oral selective PLK4 Inhibitor
Repare completed enrolment of 29 patients in its Phase 1 LIONS clinical trial, evaluating RP-1664 as a monotherapy in adult and adolescent patients with TRIM37-high solid tumors. LIONS is a first-in-human, multicenter, open-label Phase 1 clinical trial designed to investigate safety, pharmacokinetics, pharmacodynamics and the preliminary efficacy of RP-1664.
Upcoming expected milestone:
Article content
Lunresertib (RP-6306)
Repare is currently evaluating lunresertib in combination with Debio 0123, a highly selective, brain-penetrant, clinical WEE1 inhibitor, in patients with advanced solid tumors harboring CCNE1 amplification or FBXW7 or PPP2R1A deleterious alterations as part of an ongoing 50/50 cost sharing collaboration with Debiopharm. Repare does not intend to continue to develop lunresertib in any other trials, absent securing a partnership with a development partner.
Article content
Cash, cash equivalents and marketable securities: Cash, cash equivalents and marketable securities as of March 31, 2025 were $124.2 million, as compared to $152.8 million as of December 31, 2024. The Company believes that its cash, cash equivalents, and marketable securities are sufficient to fund its current operational plans through 2027.
Revenue from collaboration agreements: Revenue from collaboration agreements was nil and $52.4 million for the three months ended March 31, 2025 and 2024, respectively.
Research and development expense, net of tax credits (Net R&D): Net R&D expenses were $20.3 million and $33.0 million for the three months ended March 31, 2025 and 2024, respectively.
General and administrative (G&D) expenses: G&A expenses were $7.7 million and $8.6 million for the three months ended March 31, 2025 and 2024, respectively.
Net income (loss): Net loss was $30.1 million, or $0.71 per diluted share, and $13.2 million, or $0.30 per diluted share, for the three months ended March 31, 2025 and 2024, respectively.
Article content
About Repare Therapeutics Inc.
Article content
Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's clinical-stage pipeline includes RP-3467, a Phase 1 Polθ ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor; and lunresertib, a PKMYT1 inhibitor. For more information, please visit www.reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.
Article content
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are 'forward-looking statements. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the Company's out-license of its discovery platforms to DCx, including the potential benefits of the transaction and the receipt of out-licensing, clinical and commercial milestone payments and royalties under the out-license agreement; the Company's plans for exploring strategic alternatives and partnerships across the clinical portfolio, including the Company's plans to seek a partner to fund further clinical development of lunresertib and other assets; the Company's anticipated cash runway; the design, objectives, initiation, timing, progress and results of current and future preclinical studies and clinical trials of the Company's product candidates including the advancement of its three ongoing clinical trials. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company's ability to successfully pursue a strategic transaction on attractive terms, or at all; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including tariffs and other trade policies, the conflict in Ukraine and the conflict in the Middle East, fluctuations in inflation and uncertain credit and financial markets, on the Company's business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company's ability to realize the benefits of its collaboration and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission ('SEC') and the Québec Autorité des Marchés Financiers ('AMF') on March 3, 2025., and in other filings made with the SEC and AMF from time to time, including the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit reparerx.com and follow Repare on X (formerly Twitter) at @RepareRx and on LinkedIn at https://www.linkedin.com/company/repare-therapeutics/.
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
an hour ago
- CTV News
Nearly 2 in 3 say Canada should not join Trump's Golden Dome defence system: Nanos
U.S. President Donald Trump attends the UFC-316 mixed martial arts event, at the Prudential Center, Saturday, June 7, 2025, in Newark, N.J., with UFC's Dana White, left. (AP Photo/Frank Franklin II) A majority of surveyed Canadians are against joining U.S. President Donald Trump's 'Golden Dome' missile defence system, new polling from Nanos Research shows. Conducted earlier this month for CTV News, the randomized survey of 1,120 Canadian adults found that 63 per cent of respondents said Canada 'should not be part of the American Golden Dome,' and should instead prioritize spending 'on the capability of Canadian Armed Forces.' Roughly 17 per cent of respondents supported paying the required costs to join the Golden Dome, with 20 per cent telling pollsters they were unsure. Respondents aged 35-54 were marginally more likely to show support for joining the defence pact (19.8 per cent) compared to other age groups, and men were roughly twice as likely as women to do so (22.6 and 11.6 per cent, respectively). Regionally, Golden Dome support was more common in the Prairies (20.3 per cent), British Columbia (19.9 per cent) and Quebec (19.6 per cent), and least common in Atlantic Canada (12 per cent) and Ontario (13.6 per cent). Golden Dome, golden price tag Last month, Trump unveiled his plan to construct the Golden Dome, a sprawling, multilayered defence grid he said would be capable of intercepting missiles launched from around the globe, and even from space. Said to cost US$175 billion, the president later announced on social media that the grid could include protections for Canada from outside threats, but with a substantial price tag. 'I told Canada, which very much wants to be part of our fabulous Golden Dome System, that it will cost $61 Billion Dollars if they remain a separate, but unequal, Nation, but will cost ZERO DOLLARS if they become our cherished 51st State,' he wrote in a post to Truth Social on May 27. Trump Truth Social Golden Dome Canada (Image credit: Truth Social) Prime Minister Mark Carney's office told CTV News in a statement that 'the prime minister has been clear at every opportunity, including in his conversations with President Trump, that Canada is an independent, sovereign nation, and it will remain one.' Carney has separately acknowledged the Dome, saying it 'has been discussed at a high level,' but that he was 'not sure one negotiates' on defence matters like this. 'These are military decisions that have been taken in that context, and we will evaluate it accordingly,' he said in a May press conference. Methodology The survey involved a randomized sample of 1,120 Canadians aged 18 years or older, and was conducted between June 1 and 3, 2025, online and over the phone. Results were 'statistically checked and weighted by age and gender,' in keeping with the latest federal census data, as well as geographically to provide a representative sample of Canada. The survey carries a margin of error of plus or minus 2.9 percentage points, 19 times out of 20. With files from CTV News' Lynn Chaya and Mike Le Couteur
CTV News
an hour ago
- CTV News
Nova Scotia's ambitious ‘Wind West' offshore energy plan wins support with conditions
Turbines operate at the Block Island Wind Farm, Dec. 7, 2023, off the coast of Block Island, R.I. THE CANADIAN PRESS/AP-Julia Nikhinson HALIFAX — Two leading environmental groups are giving a thumbs up to Nova Scotia's ambitious plan to dramatically expand its fledgling offshore wind energy industry. But both groups were quick to add caveats. On Monday, Premier Tim Houston said the province's plan to license enough offshore wind farms to produce five megawatts of electricity would be increased eightfold to 40 megawatts, well beyond the 2.4 megawatts Nova Scotia needs. He called on Ottawa to help cover the costs of his new Wind West project, saying the excess electricity could be used to supply 27 per cent of Canada's total demand. 'Nova Scotia is on the edge of a clean energy breakthrough,' the Progressive Conservative premier said in an online video, adding the province is poised to become an 'energy superpower.' Gretchen Fitzgerald, executive director of Sierra Club Canada, said the premier's bold plan, which includes building transmission lines across the country, represents an exciting opportunity for the province. 'It could be a game-changer for the region and for Canada,' she said in an interview from Ottawa. 'But it needs to be done correctly and with consultations.' Fitzgerald said the Nova Scotia and Canadian governments must focus on securing long-term benefits from the nascent offshore wind industry because they did a poor job on that front when dealing with the offshore oil and gas sector. 'We have to make sure that we are not selling out what is a massive resource for less benefit than communities should have,' Fitzgerald said, adding that Nova Scotia continues to suffer from a high rate of energy poverty. In May of this year, utility affordability expert Roger Colton produced a report showing that 43 per cent of Nova Scotians were struggling to pay their energy bills — the highest proportion in Canada. While Fitzgerald applauded Houston's clean energy plan, she criticized what she described as the premier's populist penchant for taking decisive action before consulting with experts and the public. 'Moving from a couple hundred turbines to thousands in the next decade needs to be done in a staged way so we learn how to do this right,' she said, adding Houston appears to have adopted a ''move-fast-and-break-things mentality.' '(That) can lead to unacceptable harm to sensitive ocean life,' she said. 'From a community benefits and acceptance point of view, breaking trust can be the biggest barrier to getting to good climate solutions.' In October 2023, the Public Policy Forum released a study saying Sable Island Bank, an ocean area about 180 kilometres south of Nova Scotia, is among the world's best locations for wind energy generation. 'It and several other similarly endowed areas off the coast of Atlantic Canada hold the potential to place the region among the leading global hubs of offshore wind-powered energy development,' says the report from the independent non-profit think tank. It goes on to say that as the world shifts from a dependence on fossil fuels to forms of energy that do not emit climate-changing greenhouse gases, Atlantic Canada is facing 'a once-in-a-lifetime opportunity ... to recover an economic vitality comparable to the Age of Sail — fittingly built again on the power of wind at sea.' The report says the installation of 15 gigawatts of offshore wind generation would create about 30,000 direct jobs annually. Despite the hype, the industry must also earn acceptance from Nova Scotia's fishing industry, which in 2023 contributed $2.5 billion to the province's economy and employed 19,000 people. In Halifax, a spokesman for the Ecology Action Centre called on the provincial government to build public trust, especially with coastal communities. 'There really needs to be a priority on stakeholder engagement for all ocean users,' said senior energy co-ordinator Thomas Arnason McNeil. 'We're going to need to prioritize ecological safeguards and preserve the existing livelihoods that we have. That includes the fishing industry. That's half the economy in Nova Scotia.' Still, he said the province's big push for clean energy is on the right track, especially when it comes to building out its electricity grid to better connect with the rest of the country. If done right, the payoff would be enormous, Arnason McNeil said. 'We're talking serious job creation here and a lot of revenue potentially,' he said. 'The bottom line is that you have to do this right. (But) the prize at the end of the road is monumental in terms of the benefits.' A call for bids to build enough offshore turbines to generate five gigawatts of electricity is expected as early as this year. This report by The Canadian Press was first published June 8, 2025. Michael MacDonald, The Canadian Press
CTV News
an hour ago
- CTV News
Lunenburg, N.S., cracks open time capsule from 2000
A time capsule buried in Lunenburg, N.S. in 2000 was opened this Saturday. (CTV Atlantic/ Paul DeWitt) Twenty-five years ago, the people of Lunenburg, N.S., filled a time capsule and buried it on the town's 247th birthday. This past Saturday, the town dug up the capsule, relieving memories from a quarter-century ago. 'The Bluenose Academy partnered with the town to put the time capsule together after Y2K,' said Mayor Jamie Myra. Myra said the capsule features pictures of the Bluenose Academy, a letter from then-prime minister Jean Chretien and documents on town committee meetings and bylaws. Lunenburg time capsule The Lunenburg time capsule buried in 2000 was opened on Saturday, June 7, 2025. (CTV Atlantic/ Paul DeWitt) Councillor Debbie Dauphinee said her father David Dauphinee, who is a former deputy mayor for the town, put a letter in the capsule for his grandson. Myra said the town plans to refill another time capsule this fall. For more Nova Scotia news, visit our dedicated provincial page
